By Fineline Cube President Donald Trump announced new agreements with nine pharmaceutical companies to lower prescription drug prices for Americans, aligning them with the lowest prices paid by other developed nations under the most-favored-nation (MFN) pricing framework. The additions bring the total number of pharmaceutical manufacturers with MFN deals to 26, now covering 89% of the branded drug market — and grant every state Medicaid program access to MFN pricing on products from the nine newly signed companies.
Policy Milestone
| Item | Detail |
|---|---|
| Announcement | New MFN pricing agreements with nine pharmaceutical companies |
| Announced By | President Donald Trump |
| Date | 31 Aug 2026 |
| Cumulative MFN Deals | 26 pharmaceutical manufacturers |
| Market Coverage | 89% of the branded drug market |
| Key Beneficiary | Every state Medicaid program; projected billions of dollars in savings for Americans |
Participating Companies — The Nine New MFN Signatories
- Alcon
- Astellas
- BeOne
- BridgeBio
- CSL
- Kyowa Kirin
- Sun Pharma
- Teva Pharmaceuticals
- UCB
Market Impact & Outlook
- Near-Universal Branded Coverage: With 26 manufacturers signed and 89% of the branded market covered, MFN pricing has moved from policy proposal to structural feature of the US prescription drug landscape
- Medicaid Savings Engine: State Medicaid programs’ access to MFN pricing across the nine new companies is expected to generate billions of dollars in savings, easing budget pressure on state healthcare systems
- Pricing Reset for Specialty and Generics Players: The signatory list spans ophthalmology (Alcon), rare disease (BridgeBio), plasma-derived therapies (CSL), oncology generics (Sun Pharma, Teva), and neurology/inflammation (UCB, Kyowa Kirin) — signaling breadth across both specialty and volume segments
- Revenue Implications: Companies joining MFN frameworks trade lower US list prices for maintained market access — a calculation increasingly hard to refuse as participation approaches critical mass
- Industry Precedent: With 89% coverage achieved, remaining holdouts face mounting pressure to negotiate, potentially completing near-total MFN alignment of the US branded market
Forward‑Looking Statements — This brief contains forward-looking statements regarding policy implementation, pricing effects, and projected savings that involve risks and uncertainties. Actual outcomes may differ materially. Nothing herein constitutes investment advice.-Fineline Info & Tech